scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1028031188 |
P356 | DOI | 10.1186/2162-3619-2-5 |
P932 | PMC publication ID | 3585848 |
P698 | PubMed publication ID | 23422286 |
P5875 | ResearchGate publication ID | 235668733 |
P2093 | author name string | Neil Hawkins | |
Stuart Mealing | |||
Catherine Davis | |||
James Clark | |||
Ishan Hirji | |||
Leticia Barcena | |||
Victoria Eaton | |||
P2860 | cites work | Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials | Q58179557 |
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials | Q83981223 | ||
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia | Q84823041 | ||
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | Q29614280 | ||
Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 | ||
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati | Q30357011 | ||
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia | Q33393383 | ||
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data | Q33436401 | ||
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. | Q33886162 | ||
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis | Q33979738 | ||
Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 | ||
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia | Q34620246 | ||
Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews | Q37433313 | ||
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. | Q37888895 | ||
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia | Q43043759 | ||
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience | Q44045908 | ||
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study | Q44912433 | ||
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia | Q46090252 | ||
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. | Q46419894 | ||
P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P921 | main subject | imatinib | Q177094 |
dasatinib | Q419940 | ||
chronic myeloid leukemia | Q729735 | ||
dasatinib monohydrate | Q27139135 | ||
P304 | page(s) | 5 | |
P577 | publication date | 2013-02-19 | |
P1433 | published in | Experimental Hematology & Oncology | Q23979095 |
P1476 | title | The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis | |
P478 | volume | 2 |
Q28649477 | A polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathway |
Q93092100 | BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? |
Q36290275 | Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib |
Q38936993 | First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis |
Q33794548 | Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis |
Q58859336 | How low can you go? A current perspective on low-abundance proteomics |
Q41575103 | Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. |
Q35225342 | Successful nilotinib treatment in a child with chronic myeloid leukemia |
Q38748512 | Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia |
Search more.